Stifel Financial
JNCE

Stifel Financial’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Stifel Financial’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,374
Closed -$212K – 3538
2021
Q4 		$212K Buy
+25,374
New +$209K ﹤0.01% 3121
2020
Q1 		– Sell
-14,816
Closed -$131K – 3142
2019
Q4 		$131K Buy
+14,816
New +$80.1K ﹤0.01% 2856

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Stifel Financial's JNCE Position: Q1 2022 in Review

Stifel Financial sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 25,374 shares — an estimated $212K sold.

Stifel Financial first reported a position in JNCE in Q4 2019 and held it in 2 quarters. The position peaked at $212K in Q4 2021. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Stifel Financial reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Stifel Financial sold 25,374 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $212K.
  • Stifel Financial first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Stifel Financial's Jounce Therapeutics, Inc. Common Stock position peaked at $212K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Stifel Financial's 13F filing for Q1 2022, filed 13 May 2022.